Evidence map›Paper›PMID 20568270›Full record

ReviewBirth defects research. Part A, Clinical and molecular teratology2010

Epigenomic disruption: the effects of early developmental exposures.

Autumn J Bernal, Randy L Jirtle

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Birth defects research. Part A, Clinical and molecular teratology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Autumn J BernalDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Randy L Jirtle

Funding

TUMOR SUPPRESSOR FUNCTION OF THE M6P/IGF2 RECEPTORR01ES008823 · NIEHS · DUKE UNIVERSITY · PI JIRTLE, RANDY L · 1997 to 2007
$2.2M
Dietary Supplements, Imprint Gene Expression and CancerR21ES013053 · NIEHS · DUKE UNIVERSITY · PI JIRTLE, RANDY L · 2004 to 2006
$458k
NIEHS NIH HHS 5R01-ES008823NIEHS NIH HHS R01 ES008823NIEHS NIH HHS R21 ES013053
6 · The paper itself

Abstract

Through DNA methylation, histone modifications, and small regulatory RNAs the epigenome systematically controls gene expression during development, both in utero and throughout life. The epigenome is also a very reactive system; its labile nature allows it to sense and respond to environmental perturbations to ensure survival during fetal growth. This pliability can lead to aberrant epigenetic modifications that persist into later life and induce numerous disease states. Endocrine-disrupting compounds (EDCs) are ubiquitous chemicals that interfere with growth and development. Several EDCs also interfere with epigenetic programming. The investigation of the epigenotoxic effects of bisphenol A (BPA), an EDC used in the production of plastics and resins, has further raised concern over the impact of EDCs on the epigenome. Using the Agouti viable yellow (A(vy)) mouse model, dietary BPA exposure was shown to hypomethylate both the A(vy) and the Cabp(IAP) metastable epialleles. This hypomethylating effect was counteracted with dietary supplementation of methyl donors or genistein. These results are consistent with reports of BPA and other EDCs causing epigenetic effects. Epigenotoxicity could lead to numerous developmental, metabolic, and behavioral disorders in exposed populations. The heritable nature of epigenetic changes also increases the risk for transgenerational inheritance of phenotypes. Thus, epigenotoxicity must be considered when assessing these compounds for safety.

Indexed as

Embryonic DevelopmentEpigenesis, GeneticEpigenomicsAnimalsBenzhydryl CompoundsBiosensing TechniquesBisphenol A CompoundsEndocrine DisruptorsFemaleMaleMiceMice, Inbred StrainsModels, AnimalPhenolsToxicogeneticsBenzhydryl Compoundsbisphenol ABisphenol A CompoundsEndocrine DisruptorsPhenols

Identifiers

PMID20568270
PMCPMC2945443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.